What Makes a "Breakthrough" Therapy? FDA Says More Details Are Coming
This article was originally published in RPM Report
Executive Summary
FDA’s Janet Woodcock believes the agency will be able to provide more concrete parameters around what constitutes a “Breakthrough” product in its final guidance document on the agency’s expedited programs. Maybe that will help lower the rate of denials.
You may also be interested in...
Covering Breakthroughs: Payors in New Territory
FDA has granted more than two dozen “Breakthrough Therapy” designations. Not everyone is sure that’s a great thing. Payors, in particular, are getting “nervous” about what hyperfast development of hyper-expensive therapies will mean.
FDA Issues Wave Of "Breakthrough Therapy" Denials
FDA denied 10 requests for breakthrough therapy within a four-week period. The reasons behind the wave of rejections are unclear, but may be inherent to the rollout of the program.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?